Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (COMBAT-ALS)
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Sponsor: MediciNova
Listed as NCT04057898, this PHASE2/PHASE3 trial focuses on Amyotrophic Lateral Sclerosis and remains ongoing. Sponsored by MediciNova, it has been updated 37 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
37 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Oct 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Nov 2024 — Jun 2025 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 32 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2023 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2023 — Nov 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2022 — Mar 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Sep 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MediciNova
For direct contact, visit the study record on ClinicalTrials.gov .